A Single High Dose of Oral Vitamin D3 Is Not Enough to Correct Insufficiency and Deficiency in a Rheumatologic Population
Détails
ID Serval
serval:BIB_7007BD2E376C
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Poster: résume de manière illustrée et sur une page unique les résultats d'un projet de recherche. Les résumés de poster doivent être entrés sous "Abstract" et non "Poster".
Collection
Publications
Institution
Titre
A Single High Dose of Oral Vitamin D3 Is Not Enough to Correct Insufficiency and Deficiency in a Rheumatologic Population
Titre de la conférence
Annual Meeting of the Swiss Society of Rheumatology
Adresse
Fribourg, Switzerland, September 8-10, 2010
ISBN
1424-3997
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
140
Série
Swiss Medical Weekly
Pages
4S-5S
Langue
anglais
Résumé
Introduction: Vitamin D plays a major role in bone metabolism and
neuromuscular function. Supplementation with vitamin D is effective to
reduce the risk of fall and of fracture. However adherence to oral daily
vitamin D supplementation is low. Screening and correcting vitamin D
insufficiency in a general rheumatologic population could improve both
morbidity and quality of life in these patients with chronic painful
disorders and at high risk of osteoporosis. After determining the
prevalence of vitamin D deficiency in this population, we evaluated if
supplementation with a single high dose of oral 25-OH vitamin D3 was
sufficient to correct this abnormality.
Methods: During one month (November 2009), levels of 25-OH
vitamin D were systematically determined in our rheumatology
outpatient clinic and classified into three groups: vitamin D deficiency
(<10 μg/l), vitamin D insufficiency (10 to 30 μg/l) or normal vitamin D
(>30 μg/l). Patients with insufficiency or deficiency received
respectively a single high dose of 300000 IU or 600000 IU oral vitamin
D3. In addition, all patients with osteoporosis were prescribed daily
supplement of calcium (1 g) and vitamin D (800 IU). 25-OH vitamin D
levels were reevaluated after 3 months.
Results: Vitamin D levels were initially determined in 292 patients
(mean age 53, 211 women, 87% Caucasian). 77% had inflammatory
rheumatologic disease (IRD), 20% osteoporosis (OP) and 12%
degenerative disease (DD). Vitamin D deficiency was present in 20
(6.8%), while 225 (77.1%) had insufficiency. Of the 245 patients with
levels <30 μg/l, a new determination of vitamin D level was available in
173 (71%) at 3 months.
Conclusion: Vitamin D insufficiency is highly prevalent in our
rheumatologic population (84%), and is not adequately corrected by a
single high dose of oral vitamin D3 in more than half of the patients
with IRD and DD. In patients with OP, despite association of a single
high dose with daily oral vitamin D supplementation, 40% of patients
are still deficient when reevaluated at 3 months.
neuromuscular function. Supplementation with vitamin D is effective to
reduce the risk of fall and of fracture. However adherence to oral daily
vitamin D supplementation is low. Screening and correcting vitamin D
insufficiency in a general rheumatologic population could improve both
morbidity and quality of life in these patients with chronic painful
disorders and at high risk of osteoporosis. After determining the
prevalence of vitamin D deficiency in this population, we evaluated if
supplementation with a single high dose of oral 25-OH vitamin D3 was
sufficient to correct this abnormality.
Methods: During one month (November 2009), levels of 25-OH
vitamin D were systematically determined in our rheumatology
outpatient clinic and classified into three groups: vitamin D deficiency
(<10 μg/l), vitamin D insufficiency (10 to 30 μg/l) or normal vitamin D
(>30 μg/l). Patients with insufficiency or deficiency received
respectively a single high dose of 300000 IU or 600000 IU oral vitamin
D3. In addition, all patients with osteoporosis were prescribed daily
supplement of calcium (1 g) and vitamin D (800 IU). 25-OH vitamin D
levels were reevaluated after 3 months.
Results: Vitamin D levels were initially determined in 292 patients
(mean age 53, 211 women, 87% Caucasian). 77% had inflammatory
rheumatologic disease (IRD), 20% osteoporosis (OP) and 12%
degenerative disease (DD). Vitamin D deficiency was present in 20
(6.8%), while 225 (77.1%) had insufficiency. Of the 245 patients with
levels <30 μg/l, a new determination of vitamin D level was available in
173 (71%) at 3 months.
Conclusion: Vitamin D insufficiency is highly prevalent in our
rheumatologic population (84%), and is not adequately corrected by a
single high dose of oral vitamin D3 in more than half of the patients
with IRD and DD. In patients with OP, despite association of a single
high dose with daily oral vitamin D supplementation, 40% of patients
are still deficient when reevaluated at 3 months.
Création de la notice
07/03/2011 15:10
Dernière modification de la notice
20/08/2019 14:28
Données d'usage
